Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing market, Industry Analysis, and Forecast to 2035

Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors

Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.

The report features an extensive study on the extensive study of the current landscape and the likely future potential of viral vector, non-viral vector and gene therapy manufacturing market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

 An overview of the current status of the market with respect to the players engaged in the manufacturing of viral, non-viral and other novel types of vectors and gene therapies. It features information on the year of establishment, company size, location of headquarters, type of product manufactured, location of manufacturing facilities, type of manufacturers, scale of operation, type of vector manufactured and application area
 An analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology, type of manufacturer, scale of operation, type of vector involved, application area. It also highlights the most prominent players within this domain, in terms of number of technologies.
 A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of vectors and gene therapies, across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on experience in this field), manufacturing strength, service strength.
 Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on proprietary criterion). Each profile features an overview of the company / organization, its financial performance (if available), information related to its manufacturing facilities, vector manufacturing technology and an informed future outlook.
 Tabulated profiles of the other key players headquartered in different regions across the globe (shortlisted based on proprietary criterion). Each profile features an overview of the company, its financial performance (if available), information related to its manufacturing capabilities, and an informed future outlook.
 An analysis of partnerships and collaborations established in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, which were analyzed on the basis of year of partnership, type of partnership, scale of operation, type of vector involved, region and most active players.
 An analysis of the expansions related to viral vector and non-viral vector manufacturing, which have been undertaken since 2015, based on several parameters, such as year of expansion, type of expansion, type of vector and geographical location of the expansion.
 An analysis evaluating the potential strategic partners for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength.
 An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
 An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations, a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and type of manufacturer, a heat map of viral vector and plasmid DNA manufacturers based on the type of vector and type of organization, and a schematic world map representation, highlighting the headquarters and geographical location of key vector manufacturing hubs.
 An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
 An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size, scale of operation, type of vector and region.
 An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
 A discussion on the factors driving the market and various challenges associated with the vector production process.
 A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of drug developers, bargaining power of vector and gene therapy manufacturers, threats of substitute technologies and rivalry among existing competitors.

By 2035, the financial opportunity within the viral vector manufacturing, non-viral vector manufacturing and gene therapy manufacturing market has been analyzed across the following segments:
 Scale of Operation
 Lab
 Clinical
 Commercial

 Type of Vectors
 AAV
 Adenoviral
 Lentiviral
 Retroviral
 Plasmid DNA
 Other Vectors

 Application Area
 Gene Therapy
 Cell Therapy
 Vaccines

 Therapeutic Area
 Oncological Disorders
 Rare Disorders
 Neurological Disorders
 Sensory Disorders
 Metabolic Disorders
 Musco-skeletal Disorders
 Blood Disorders
 Immunological Diseases
 Others

 Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 MENA
 Rest of the World

Key Companies covered in the report
 Advanced BioScience Laboratories
 Aldevron
 Audentes Therapeutics
 BioNTech Innovative Manufacturing
 BioReliance
 Biovian
 bluebird bio
 Cell and Gene Therapy Catapult
 Celonic
 Centre for Process Innovation
 Cobra Biologics
 Emergent BioSolutions
 FinVector
 FUJIFILM Diosynth Biotechnologies
 Kaneka Eurogentec
 Lonza
 MeiraGTx
 MolMed
 Novasep
 Orchard Therapeutics
 Oxford BioMedica
 Richter-Helm
 Sanofi
 Spark Therapeutics
 Thermo Fisher Scientific
 uniQure
 Vibalogics
 Vigene Biosciences
 VIVEbiotech
 Wuxi AppTech


To view more details on this report, click on the link:
https://www.rootsanalysis.com/....reports/view_documen

You may also be interested in the following titles:
Lab Automation Market

Cannabis Testing Market


You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders

4D Bioprinting Market: Key Trends


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
#viralvectormanufacturingmarketsize #viralvectormanufacturingmarkettrends #viralvectors #nonviralvectors #nonviralvectorsforgenetherapy